EGFR and non-small cell lung carcinoma: The randomized phase II part compared tepotinib plus gefitinib versus chemotherapy in patients with EGFR-mutant (T790M−negative) NSCLC harboring MET overexpression or METamp, who had failed prior EGFR-TKI therapy.